Budesonide (inhalation)
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral, Nasal, tracheal, rectal |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 100% (but large first pass effect) |
| Protein binding | 85-90% |
| Metabolism | Hepatic CYP3A4 |
| Elimination half-life | 2.0-3.6 hours |
| Excretion | Renal, Faecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C25H34O6 |
| Molar mass | 430.534 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Budesonide is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis. Additionally, it is used for inflammatory bowel disease. It is marketed by AstraZeneca as a nasal inhalation with the brand name Rhinocort (in Denmark, as Rhinosol), as an oral inhalation with the brand name Pulmicort, and as an enema and a modified-release capsule with the brand name Entocort. It is also sold in combination with formoterol (Oxis) in a single inhaler, with the brand name Symbicort.
Pharmacology
Budesonide has a high first pass metabolism. It has efficacy in the terminal ileum and the right colon. Budesonide in comparison with prednisolone has been associated with fewer bone density losses and unlike other corticosteroids has little influence on the hypothalamic-pituitary-adrenal axis which also limit the need of tapering before discontinuation. Overall, it has a lower incidence of systemic manifestations than similar medications.
Side Effects
Budesonide may cause:
- nose irritation or burning
- bleeding or sores in the nose
- lightheadedness
- upset stomach
- cough
- hoarseness
- dry mouth
In addition the following should be reported:
- Immediately if difficulty breathing or swelling of the face
- white patches in the throat, mouth, or nose
- irregular menstrual periods
- severe acne
Recall
Pulmicort inhalers were recalled in 2002 because there was concern that they may not always have provided the full dosage.
External links
Template:Antidiarrheals, intestinal anti-inflammatory/anti-infective agents
Template:Asthma and copd rx Template:Corticosteroids Template:SIB
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Glucocorticoids
- Asthma
- Pulmonology